Editas Medicine

Thank you to everyone who joined us last week at Cell & Gene Therapy World Asia 2026. It was a pleasure connecting with colleagues from across the cell and gene therapy community and sharing insights on the value of early CMC integration. #CGTAsia2026 #CGTWA2026 #CMC #biotech

It was great to participate in this year’s European Congress on Biotechnology. We enjoyed connecting with researchers, innovators, and industry leaders from across the biotechnology community to discuss the future of genetic medicines. #ECB2026 #biotechnology #geneediting #invivo

Last week, Team Editas participated in the annual J.P. Morgan Corporate Challenge. It was a great opportunity to connect with colleagues and celebrate teamwork beyond the workplace. Thank you to everyone who participated and represented Editas Medicine! #JPMCorporateChallenge

Next week, we'll present at Cell & Gene Therapy World Asia 2026 with our session, "Designing for Development: The Role of Early CMC Integration in Product Lifecycle Success." See you in Singapore! #CGTAsia2026 #CGTWA2026 #CellAndGeneTherapy #CMC #Biomanufacturing

Join us next week at the European Congress on Biotechnology for our keynote lecture, "A Walk Through the Evolution of Genetic Medicines," exploring advances in gene editing, delivery, and manufacturing that are shaping the future of genetic medicines. #ECB2026 #biotechnology

Next week, our President & CEO, Gilmore O’Neill, will join fellow industry leaders at the Longwood Healthcare Leaders MIT CEO 2026 Meeting for a panel on “Pipeline Prioritization.” We look forward to an insightful discussion! #LongwoodHealthcareLeaders #MITCEO #biotech

We’re excited to attend the 2026 National Lipid Association Sessions in Chicago this week, where we’ll present preclinical data on our lead in vivo development candidate, EDIT-401. #NLASessions #cardiovasculardisease #invivo #geneediting

Yesterday, Editas Medicine President & CEO, Gilmore O’Neill, presented at the 2026 Jefferies Global Healthcare Conference, where he highlighted the latest updates on the EDIT-401 program. Listen to the presentation here: bit.ly/4nqnhuq. #Jefferies2026

Editas successfully completed an up to $319.4M public offering. This milestone marks an exciting new chapter as we continue to advance EDIT-401 and drive towards our goal of delivering transformative medicines to people living with serious diseases. bit.ly/49YSY8u

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference. For details, read the full press release here: bit.ly/49n7Cq0. #JefferiesHealthcare #cardiovasculardisease #biotech #invivo

At #EASCongress2026 earlier this week, we presented new preclinical data supporting the continued advancement of our lead in vivo development candidate, EDIT-401. View the press release here: bit.ly/4agcD3R. #invivo #geneediting #cardiovasculardisease

#NEWS: Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress. Read the press release here: bit.ly/4dFI2PD. #EASCongress2026 #invivo

We’re excited to attend the 94th European Atherosclerosis Society Congress in Athens next week, where we’ll present new preclinical data on our lead in vivo development candidate, EDIT-401. For more details, read here: bit.ly/4w8kc62. #EASCongress2026 #invivo

It was a pleasure to participate in #ASGCT2026 and #TIDESUSA last week, where we were excited to share new preclinical data for our lead in vivo development candidate, EDIT-401. Thank you to everyone who spent time with the Editas team! #invivo #cardiovasculardisease #biotech

This week at #ASGCT2026, we presented new preclinical data supporting the continued advancement of our lead in vivo development candidate, EDIT-401, as well as the broader potential of our differentiated upregulation strategy. View the presentations here: bit.ly/3RbSqFI.

Join us today as we present new preclinical data from our lead in vivo development candidate, EDIT-401, in an oral presentation at #ASGCT2026. #invivogeneediting #cardiovasculardisease #biotechnology

#NEWS: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting. Read the press release for details: bit.ly/4dIHHve. #ASGCT2026 #invivo

Today we’re at the TIDES USA 2026 Meeting, where we’ll be sharing more information on our lead in vivo development candidate, EDIT-401, in an oral presentation. For details, visit the TIDES website: bit.ly/4neYOIi. #TIDESUSA #invivo #geneediting #cardiovasculardisease

Attending ASGCT? Check out our posters featured during the Wednesday and Thursday Poster Receptions from 5:00 p.m. – 6:30 p.m. EDT in the Exhibit and Poster Hall. For more information on the presentations, read here: bit.ly/4w8kc62. #ASGCT2026 #geneediting #healthcare

This week, we’ll be presenting new preclinical data at the American Society of Gene and Cell Therapy and TIDES USA annual meetings. For more details on our presence at each conference, read here: bit.ly/4w8kc62. #ASGCT2026 #TIDESUSA #invivo #cardiovasculardisease